Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies - 13/12/18
Abstract |
Background |
Wide-ranging prevalence estimates of psoriatic arthritis (PsA) in patients with psoriasis have been reported.
Objectives |
To assess the prevalence and incidence of PsA in patients with psoriasis.
Methods |
Two authors independently searched 3 databases for studies reporting on the prevalence or incidence of PsA in patients with psoriasis. A proportion meta-analysis was performed to calculate the pooled proportion estimates of PsA in patients with psoriasis.
Results |
A total of 266 studies examining 976,408 patients with psoriasis were included. Overall, the pooled proportion (95% confidence interval [CI]) of PsA among patients with psoriasis was 19.7% (95% CI, 18.5%-20.9%). In children and adolescents (<18 years of age), the pooled prevalence was 3.3% (95% CI, 2.1%-4.9%). The PsA prevalence was 22.7% (95% CI, 20.6%-25.0%) in European patients with psoriasis, 21.5% (95% CI, 15.4%-28.2%) in South American patients with psoriasis, 19.5% (95% CI, 17.1%-22.1%) in North American patients with psoriasis, 15.5% (95% CI, 0.009%-51.5%) in African patients with psoriasis, and 14.0% (95% CI, 95% CI, 11.7%-16.3%) in Asian patients with psoriasis. The prevalence of PsA was 23.8% (95% CI, 20.1%-27.6%) in studies in which the Classification Criteria for Psoriatic Arthritis were applied. The incidence of PsA among patients with psoriasis ranged from 0.27 to 2.7 per 100 person-years.
Limitations |
Between-study heterogeneity may have affected the estimates.
Conclusions |
We found that 1 in 4 patients with psoriasis have PsA. With the growing recognition of the Classification Criteria for Psoriatic Arthritis, more homogenous and comparable prevalence estimates are expected to be reported.
Le texte complet de cet article est disponible en PDF.Key words : arthritis, arthropathy, incidence, prevalence, psoriasis, psoriatic
Abbreviations used : CASPAR, CI, HLA, JIA, PsA
Plan
| Funding sources: None. |
|
| Disclosure: Dr Kristensen has received fees for speaking and consultancy from Pfizer, MSD, AbbVie, UCB, Eli Lilly and Company, Novartis, Celgene, Janssen Pharmaceuticals, Roche, Forward Pharma, and BMS. Dr Gladman has received consultancy fees and/or grant support from AbbVie, Amgen, BMS, Celgene, Eli Lilly and Company, Janssen, Pfizer, Novartis, and UCB. Dr Jullien has received research funding from Pfizer and honoraria as a consultant and/or speaker from Abbvie, Amgen, Celgene, Eli Lilly and Company, Janssen Pharmaceuticals, MSD, Novartis, and Pfizer. Dr Gottlieb has received honoraria as a consultant and/or speaker from Janssen Inc, Celgene Corp, Bristol-Myers Squibb, Beiersdorf Inc, Abbvie, UCB, Novartis, Incyte, Eli Lilly and Company, Reddy Labs, Valeant, Dermira, Allergan, and Sun Pharmaceutical Industries, and he has received research funding from Janssen, Incyte, Eli Lilly and Company, Novartis, Allergan, and Leo Pharma. Dr Gisondi has received honoraria as a consultant and/or speaker from AbbVie, Celgene, Eli Lilly and Company, Janssen, Leo Pharma, MSD, Novartis, Pfizer, and UCB. Dr Wu is an investigator for AbbVie, Amgen, Eli Lilly and Company, Janssen, Novartis, and Regeneron. Dr Thyssen is supported by an unrestricted grant from the Lundbeck Foundation; he has received speaker honoraria from Galderma, Sanofi-Genzyme, and MEDA; has attended advisory board meetings for Roche and Sanofi-Genzyme; and is an investigator for LEO Pharma. Dr Egeberg has received research funding from Pfizer, Eli Lilly and Company, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation and has received honoraria as a consultant and/or speaker from Almirall, Leo Pharma, Samsung Bioepis Co Ltd, Pfizer, Eli Lilly and Company, Novartis, Galderma, and Janssen Pharmaceuticals. Drs Alinaghi, Calov, and Coates have no conflicts of interest to disclose. |
|
| Drs Alinaghi and Calov had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Egeberg and Thyssen take responsibility for study concept and design. All the authors take responsibility for acquisition, analysis, and interpretation of the data and for critical revision of the manuscript for important intellectual content. Drs Alinaghi and Egeberg take responsibility for drafting of the manuscript. Dr Egeberg takes responsibility for statistical analysis. Drs Egeberg and Thyssen take responsibility for administrative, technical, or material support and for study supervision. |
|
| Reprints not available from the authors. |
Vol 80 - N° 1
P. 251 - janvier 2019 Retour au numéro
Article précédent
- Guidelines of care for the management of primary cutaneous melanoma
- Work Group, Susan M. Swetter, Hensin Tsao, Christopher K. Bichakjian, Clara Curiel-Lewandrowski, David E. Elder, Jeffrey E. Gershenwald, Valerie Guild, Jane M. Grant-Kels, Allan C. Halpern, Timothy M. Johnson, Arthur J. Sober, John A. Thompson, Oliver J. Wisco, Samantha Wyatt, Shasa Hu, Toyin Lamina
- Review of environmental effects of oxybenzone and other sunscreen active ingredients
- Samantha L. Schneider, Henry W. Lim
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?